AbbVie Inc. (NYSE:ABBV), a global biopharmaceutical company, develops and sells prescription medications for various health conditions, focusing on chronic autoimmune diseases, oncology ...

AbbVie stock (NYSE: ABBV) has more than doubled in value since early January 2021 – jumping from levels of $90 then to around $195 now – vs. an increase of about 50% for the S&P 500 over this ...

In this article, we are going to take a look at where AbbVie Inc (NYSE:ABBV) stands against the other 52-week high stocks. The U.S. stock market has been on a roll, with major indices clocking ...

After a strong seventh-place showing at Darlington Raceway, Shane Van Gisbergen is putting on display just how quickly he can learn an entirely new discipline. / Mark J. Rebilas-USA TODAY Sports ...

For instance, the price of AbbVie Inc. (NYSE:ABBV) stock is up an impressive 190% over the last five years. On top of that, the share price is up 22% in about a quarter. This could be related to ...

Here’s what’s coming next. Study results are expected for two closely watched obesity drugs, while key tests await for a high-priced AbbVie acquisition and one of 2023’s largest IPOs.

AbbVie's stock has risen to an all-time high, raising the question of whether it's still a good buy, especially as the market multiples look elevated from a historical perspective. Progress on its ...

AbbVie's Qulipta gains ground with docs for migraine prevention, as pharma looks to pressure Biohaven's Nurtec The top-selling CGRP is Pfizer’s Nurtec, which rang up sales of $928 million last year.

AbbVie shares are nearing $200, likely facing resistance and a potential pullback to test support between $175 and $185. Despite strong dividends and share buybacks, AbbVie’s higher P/E ratio ...

Eli Lilly is exploring whether its newest hit drug could be used to treat psoriasis. AbbVie's newest hit drugs already treat psoriasis, among other conditions. It usually isn't good news for a ...

Analysts expect the FDA to clear KarXT for market by the end of September. Though farther behind, AbbVie is also trying to bring a muscarinic drug to market. Called emraclidine, the drug is in ...

ABBV-932 is under clinical development by AbbVie and currently in Phase I for Schizophrenia. According to GlobalData, Phase I drugs for Schizophrenia have a 66% phase transition success rate (PTSR) ...